## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the applications:

## **Listing of Claims:**

- 1-11. (Canceled)
- 12. (New) A method of treating essential tremor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof.
- 13. (New) The method of claim 12, wherein the essential tremor is severe essential tremor.
- 14. (New) The method of claim 12, wherein the therapeutically effective amount is in the range of about 0.5 mg/kg/day to about 10 mg/kg/day.
- 15. (New) The method of claim 12, wherein the pharmaceutical composition is administered orally to the subject.
- 16. (New) The method of claim 12, wherein the pharmaceutical composition is administered parenterally to the subject.
- 17. (New) The method of claim 16, wherein the pharmaceutical composition is a sterile solution comprising zonisamide sodium.
- 18. (New) The method of claim 16, wherein the pharmaceutical composition is administered intravenously, subcutaneously, or intramuscularly.
- 19. (New) The method of claim 12, further comprising administering another therapeutic agent used to treat essential tremor.
- 20. (New) The method of claim 12, further comprising administering propranolol, timolol, alprazolam, clonazepam, diazepam, lorazepam, trazadone, mirtazapine, clonidine, a botulinum toxin injection, gabapentin, primidone, phemobarbital or MK-801.

- 21. (New) A method for treating severe essential tremor in the rest state in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof.
- 22. (New) The method of claim 21, wherein the therapeutically effective amount is in the range of about 0.5 mg/kg/day to about 10 mg/kg/day.
- 23. (New) The method of claim 21, wherein the pharmaceutical composition is administered orally to the subject.
- 24. (New) The method of claim 21, wherein the pharmaceutical composition is administered parenterally to the subject.
- 25. (New) The method of claim 24, wherein the pharmaceutical composition is a sterile solution comprising zonisamide sodium.
- 26. (New) The method of claim 24, wherein the pharmaceutical composition is administered intravenously, subcutaneously, or intramuscularly.
- 27. (New) The method of claim 24, further comprising administering another therapeutic agent used to treat severer essential tremor in the rest state.
- 28. (New) The method of claim 21, further comprising administering propranolol, timolol, alprazolam, clonazepam, diazepam, lorazepam, trazadone, mirtazapine, clonidine, a botulinum toxin injection, gabapentin, primidone, phemobarbital or MK-801.
- 29. (New) A method for treating action tremor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof.
  - 30. (New) The method of claim 29, wherein the action tremor is postural tremor.
- 31. (New) The method of claim 29, wherein the action tremor is drug-induced or toxic tremor; primary orthostatic tremor; dystonic tremor; or neuropathic tremor.
  - 32. (New) The method of claim 29, wherein the action tremor is cerebellar tremor.

Response and Amendment under 37 CFR § 1.111 US Application No. 10/663,187 Page 4 of 10

- 33. (New) The method of claim 29, wherein the therapeutically effective amount is in the range of about 0.5 mg/kg/day to about 10 mg/kg/day.
- 34. (New) The method of claim 29, wherein the pharmaceutical composition is administered orally or parenterally to the subject.
- 35. (New) A method for treating kinetic tremor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof.